glp-1 next generation therapies evolving to multi-hormone action | Mahesh Malhotra posted on the topic How are GLP-1 drugs reshaping

Weight loss drugs have shown impressive short-term results, but new research suggests their benefits may be difficult to sustain once treatment ends

[DOI] [PubMed] [Google Scholar] 80.Haywood C., Sumithran P

Tirzepatide (Mounjaro, Zepbound) works through a related but distinct mechanism as a dual GIP/GLP-1 receptor agonist

Tidigare allvarlig pankreatit - tidiga studier visade p en mjlig koppling mellan bukspottkrtelinflammation (pankreatit) och anvndande av GLP-1-analoger

Optum Perks is owned by RVO Health

Retatrutide incorporates a fatty acid modification to enhance its stability and extend its half-life to six days, enabling weekly dosing [16]